RecruitingPhase 2NCT07136857
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
Studying Glanzmann thrombasthenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emory University
- Principal Investigator
- Karen Zimowski, MDEmory University
- Intervention
- EPTACOG BETA(drug)
- Enrollment
- 6 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Arthur M. Blank Hospital | Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Collaborators
Laboratoire Français du Fractionnement et des Biotechnologies (LFB BIOTECHNOLOGIES)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07136857 on ClinicalTrials.govOther trials for Glanzmann thrombasthenia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06820515ATHNdataset RegistryAmerican Thrombosis and Hemostasis Network
- RECRUITINGNANCT04119908Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic DiseasesUniversity Hospital, Lille
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06211634A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann ThrombastheniaHemab ApS
- RECRUITINGNCT00230165The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.Rockefeller University